198 related articles for article (PubMed ID: 19203729)
21. Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm.
Chan SY; Hughes RM; Woo K; Perales MA; Neofytos D; Papanicolaou G
Med Mycol; 2020 Nov; 58(8):1029-1036. PubMed ID: 32171012
[TBL] [Abstract][Full Text] [Related]
22. [Careful: skins cancers and voriconazole].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2011 Nov; 138(11):805-6. PubMed ID: 22078051
[No Abstract] [Full Text] [Related]
23. Association between drug tolerability and medical resource use in prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplant.
Gao X; Marks DI; Schlamm HT; Ji X; Stephens JM; Tarallo M
J Med Econ; 2013 Aug; 16(8):1061-70. PubMed ID: 23730943
[TBL] [Abstract][Full Text] [Related]
24. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
25. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
[TBL] [Abstract][Full Text] [Related]
26. Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients.
Shang W; Feng G; Sun R; Wang X; Liu W; Zhang S; Li J; Pang X; Wang Y; Zhang W
J Clin Pharm Ther; 2012 Dec; 37(6):652-6. PubMed ID: 22725946
[TBL] [Abstract][Full Text] [Related]
27. Voriconazole-induced photosensitivity.
Malani AN; Aronoff DM
Clin Med Res; 2008 Sep; 6(2):83-5. PubMed ID: 18801950
[TBL] [Abstract][Full Text] [Related]
28. [Voriconazole safety: short review of clinical data].
Veselov AV; Belousov DIu
Antibiot Khimioter; 2006; 51(3-4):19-25. PubMed ID: 17165257
[No Abstract] [Full Text] [Related]
29. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
[TBL] [Abstract][Full Text] [Related]
30. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole.
Feist A; Lee R; Osborne S; Lane J; Yung G
J Heart Lung Transplant; 2012 Nov; 31(11):1177-81. PubMed ID: 22841559
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
33. Antifungal prophylaxis in haematology patients: the role of voriconazole.
Hicheri Y; Cook G; Cordonnier C
Clin Microbiol Infect; 2012 Apr; 18 Suppl 2():1-15. PubMed ID: 22409648
[TBL] [Abstract][Full Text] [Related]
34. New antifungal drugs and the pediatric cancer patient: current status of clinical development.
Groll AH; Lehrnbecher T
Klin Padiatr; 2005; 217(3):158-68. PubMed ID: 15858708
[TBL] [Abstract][Full Text] [Related]
35. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients.
Bhatti Z; Shaukat A; Almyroudis NG; Segal BH
Mycopathologia; 2006 Jul; 162(1):1-15. PubMed ID: 16830186
[TBL] [Abstract][Full Text] [Related]
36. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis.
Pavie J; Lacroix C; Hermoso DG; Robin M; Ferry C; Bergeron A; Feuilhade M; Dromer F; Gluckman E; Molina JM; Ribaud P
J Clin Microbiol; 2005 Sep; 43(9):4902-4. PubMed ID: 16145172
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
38. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
[TBL] [Abstract][Full Text] [Related]
39. Voriconazole-associated phototoxic dermatoses and skin cancer.
Goyal RK
Expert Rev Anti Infect Ther; 2015; 13(12):1537-46. PubMed ID: 26488688
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections.
Gorski E; Esterly JS; Postelnick M; Trifilio S; Fotis M; Scheetz MH
Antimicrob Agents Chemother; 2011 Jan; 55(1):184-9. PubMed ID: 20974867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
